Medexus Pharmaceuticals Inc.
MEDXF · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $24 | $5 | $13 | $10 |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Receivables | $13 | $24 | $22 | $14 |
| Inventory | $35 | $31 | $23 | $21 |
| Other Curr. Assets | $8 | $12 | $15 | $3 |
| Total Curr. Assets | $81 | $72 | $73 | $49 |
| Property Plant & Equip (Net) | $1 | $1 | $1 | $1 |
| Goodwill | $10 | $10 | $10 | $11 |
| Intangibles | $72 | $64 | $70 | $77 |
| Long-Term Investments | $0 | $0 | -$9 | $0 |
| Tax Assets | $9 | $8 | $7 | $0 |
| Other NC Assets | $0 | $0 | $9 | $2 |
| Total NC Assets | $91 | $83 | $88 | $90 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $172 | $156 | $161 | $139 |
| Liabilities | – | – | – | – |
| Payables | $6 | $8 | $10 | $12 |
| Short-Term Debt | $37 | $16 | $43 | $15 |
| Tax Payable | $1 | $1 | $1 | $0 |
| Deferred Revenue | $0 | $0 | $28 | $18 |
| Other Curr. Liab. | $53 | $41 | $29 | $21 |
| Total Curr. Liab. | $97 | $66 | $83 | $48 |
| LT Debt | $0 | $34 | $28 | $41 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $2 |
| Other NC Liab. | $22 | $25 | $27 | $31 |
| Total NC Liab. | $22 | $59 | $55 | $73 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $1 | $1 |
| Total Liabilities | $120 | $125 | $139 | $121 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $96 | $76 | $69 | $69 |
| Retained Earnings | -$62 | -$64 | -$64 | -$65 |
| AOCI | $6 | $6 | $6 | $4 |
| Other Equity | $12 | $12 | $11 | $10 |
| Total Equity | $52 | $30 | $22 | $18 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $172 | $156 | $161 | $139 |
| Net Debt | $13 | $45 | $58 | $46 |